A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s Disease

Autor: Vermeire, Severine A.R.A., Dewit, Olivier, Peeters, Harald, Stehlik, Jiri, Vanasek, Tomas, Laharie, David, Colombel, Jean Frederic, Bigard, Marc-André, Varga, Marta, Zeher, Margit, Novak, Janos, Hunyady, Bela, Salamon, Agnes, Racz, Istvan, Gionchetti, Paolo, Kohn, Anna, Prantera, Cosimo, Stokkers, P.C.F., Slomka, Maria, Paradowski, Leszek, Arlukowicz, Tomasz, Kuzela, Ladislav, Baricky, Boris, Hlavaty, Tibor, Vera, Maria Isabel, Panes, Julian, Guardiola, Jordi, Probert, Christopher, Shaffer, Jonathan Lionel, Fleisher, Mark, Pruitt, Ronald Edward, Sandborn, William J., Goff, John Sawyer, Weber, John, Bell, Raymond Lloyd, Zwick, Andrew Harrison, Gutierrez, Alexandra, Levine, Robert H., Hanauer, Stephen Brett, Lavelle, Lori Ann, Kottoor, Ravindranath K., Dryden, Gerald Wayne, Jr., Hardi, Robert, Glorioso, David Vaughn, Swaroop, Prabhakar, Lee, Scott D., Patrick, Teressa Joan, Scheinert, Sheldon, Sninsky, Charles A., Katz, Seymour, Noar, Mark D., Gaspari, Michael Marion, Gordon, Glenn L., Dalton, Thomas A., Homoky, Douglas Edward, Kilgore, William Ransom, III, Levien, Joel A., Schneider, Herbert R., Moola, Suleman Abdul, Kruger, Frederik Cornelius, Wright, John P., Aboo, Nazimuddin, Ghosh, Subrata, Vranic, Ivana, Wang, Wenjin, Niezychowski, Wojciech
Zdroj: In Clinical Gastroenterology and Hepatology September 2014 12(9):1485-1493
Databáze: ScienceDirect